04 October, 2026 | Sunday
BioPharma Boardroom
EirGenix's EG1206A Meets Phase 1 Trial Objectives as Breast Cancer Biosimilar

EG1206A is a biosimilar drug of the second-generation HER2-positive antibody drug Perjeta® (pertuzumab). EG1206A has a unique binding mechanism for HER...

May 03, 2023 | Wednesday | News
OBI Pharma presents OBI-999 combo and Globo H-targeted CAR T-cell immunotherapy posters at AACR 2023

OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab (anti-PD1 mAb) in...

April 10, 2023 | Monday | News

Partner Content

BioPharma BreakThrough's

Editor Picks

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
  View poll results   More polls
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
BioPharma Boardroom

About Us Media Pack Contact Us Privacy Policy

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close